Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Daiichi Sankyo Plays Down Tariff Impact for FY2025, Eyes US Production Boost
August 1, 2025
- Leqembi’s April-June Sales at 23.1 Billion Yen: Eisai
August 1, 2025
- Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners
August 1, 2025
- Takeda Sees Limited Tariff Exposure as US Remains Strategic Priority
July 31, 2025
- Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
- Kissei Licenses Thyroid Eye Disease Candidates from Viridian
July 31, 2025
- Novo Japan Files Sogroya for SGA-Related and Noonan Syndrome Short Stature
July 31, 2025
- AstraZeneca, Japanese Circulation Association Join Hands to Tackle Cardiovascular Disease
July 31, 2025
- Lilly Launches Higher-Dose Trulicity in Japan for Type 2 Diabetes
July 31, 2025
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
- Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution
July 30, 2025
- Otsuka Ups H1 Earnings Outlook on Rexulti, Other Global Brands
July 30, 2025
- Lenvima Bolsters Label for HCC in China: Eisai
July 30, 2025
- NCVC-Backed Startup Raises US$14 Million to Develop PAH Therapy
July 30, 2025
- Rakuten Launches Japan Arm of Global PIII for Photoimmunotherapy/Keytruda Combo
July 30, 2025
- Toa Eiyo Scraps TGCV Drug CNT-01 after Japan PIIb/III Miss
July 30, 2025
- Chugai Sees 20% of Workforce Apply for Internal Job Postings
July 29, 2025
- Stella to Seek Japan Approval for BNCT as Angiosarcoma Trial Hits Goal
July 29, 2025
- Deciphera’s TGCT Drug Gets Key EMA Backing: Ono
July 29, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…